|Articles|March 19, 2020
Episode 52: Cannabinoids
Author(s)Christen Harm, Elaine Quilici
Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.
Advertisement
Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition
2
FDA Approves Moderna's mRNA-Based Flu Vaccine
3
Amazon Pharmacy Launches GLP-1 Delivery Service
4
Your Questions Answered: The Biggest Pharma Stories of the Week of August 3-7, 2026
5